[Infusion of LAK cells and anticancer drugs with a total implantable port to a patient with metastatic liver and spleen tumors].
A case of hepatic and splenic metastases of lung cancer infused with LAK cells and anticancer drugs from hepatic artery with total implantable port (Port-A-Cath: Pharmacia, Incorp.) was reported. A 56-year-old male was admitted to our hospital because of general fatigue, jaundice, pleural effusion and elevation of transaminase caused by hepatic and splenic metastases of lung carcinoid. Abdominal ultrasonography revealed 6 hepatic metastatic foci 10-35 mm in diameter and splenic metastases. The patient received 5 courses of MMC infusion, CPA (2 courses) and epirubicin, CDDP (3 courses), and 5 courses of LAK cells (total 1.4 x 10(10)) with IL-2 and OK-432. Eight months after initiation of treatment, jaundice and pleural effusion disappeared, transaminase returned to the normal level and the condition of the patient improved. Although the response of hepatic metastases to the treatment was NC, the size of a splenic metastasis decreased from 35 x 55 mm to 24 x 35 mm (PR).
Kimura
H
H
Dept. of Surgery, Institute of Pulmonary Cancer Research, Chiba University.
Yamaguchi
Y
Y
Ebara
M
M
Yosikawa
M
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002276:Carcinoid Tumor / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D006801:Humans; D015918:Infusion Pumps, Implantable; D007261:Infusions, Intra-Arterial; D007376:Interleukin-2 / Q000008:administration & dosage; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation*; D008113:Liver Neoplasms / Q000556:secondary / Q000628:therapy*; D008175:Lung Neoplasms / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D010844:Picibanil / Q000008:administration & dosage; D013160:Splenic Neoplasms / Q000556:secondary / Q000628:therapy*
D007376:Interleukin-2; D010844:Picibanil